Marriott’s Fee Model Is the Real Test in a Regional Collapse
A 43% Middle East RevPAR drop shows what an asset-light model is built for.
Tesla Shareholders Hold the Only Real Veto on a SpaceX Merger
Not voting counts as a no. Here is what you would give up, and gain.
Lula’s Party Is Blocking the Spending Fix the Real Needs
The finance minister pick could reverse or deepen a week of market damage.
China’s Factory PMI Missed 50.0. Miners Face Monday.
A 49.3 reading below every major forecast puts BHP, RIO, and commodity-linked names in the crosshairs at the open.
The Nasdaq 100 Is in Correction. AI Is Being Priced as Debt.
Friday’s $1 trillion wipeout was not just a bad day for tech stocks. It was the market demanding proof that borrowed money can buy a return.
ExxonMobil Earned $15 Billion in Q3. Refining Built It.
A $4.5 billion refining lift drove the quarter, but margins are the number to question.
Brent at $116 Is the Market’s Answer to Tehran and Washington
Four tankers, two contradictory claims, and a fourth straight monthly gain that tells you which side oil traders believe.
Ford Grew Profits While Selling Fewer Cars. Here Is Why That Matters.
A 13.3% return on invested capital and $4.7 billion in free cash flow reframe what looked like a volume problem.
T-Mobile Beat Big. The Broadband Play Explains Why.
TMUS’s 34% EPS jump and raised guidance point beyond wireless.
VKTX Reports Today. Lilly Should Be Watching.
With shares down about 41% in a month and Phase 3 oral trials just launched, Viking Therapeutics is cheaper now than it has been in years, and Lilly’s antitrust overhang may matter most in any buyout talk.